CD79B Antibody (H-3): sc-373843
- CD79B Antibody (H-3) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 1-229 representing full length CD79B of human origin
- recommended for detection of CD79B of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for CD79B Antibody (H-3) for WB applications. This reagent is now offered in a bundle with CD79B Antibody (H-3) (see ordering information below).
QUICK LINKS
CD79B Antibody (H-3) is a mouse monoclonal IgG1 antibody that detects CD79B in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD79B, also known as B29, is a critical component of the B cell antigen receptor complex, functioning alongside CD79A to facilitate the signaling necessary for B cell activation and development. CD79B contains a cytoplasmic tail with an immuno-receptor tyrosine-based activation motif (ITAM) that is essential for initiating downstream signaling cascades upon antigen binding. This activation is crucial for B cell proliferation, differentiation, and the production of antibodies, making CD79B a vital player in adaptive immunity. The interaction of CD79B with membrane immunoglobulins, such as IgM and IgD, not only aids in their surface expression but also enhances their ability to present antigens effectively, thereby ensuring a robust immune response. Anti-CD79B antibody (H-3) serves as an invaluable tool for researchers studying B cell biology and the mechanisms underlying immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD79B Antibody (H-3) References:
- Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. | Thompson, AA., et al. 1999. Leuk Lymphoma. 32: 561-9. PMID: 10048429
- Analysis of the B-cell receptor B29 (CD79b) gene in familial chronic lymphocytic leukemia. | Payelle-Brogard, B., et al. 1999. Blood. 94: 3516-22. PMID: 10552962
- Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. | Gordon, MS., et al. 2000. Proc Natl Acad Sci U S A. 97: 5504-9. PMID: 10792036
- CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients. | Minuzzo, S., et al. 2005. Leukemia. 19: 1099-101. PMID: 15830006
- Suppression of humoral immunity by monoclonal antibody to CD79b, an invariant component of antigen receptors on B lymphocytes. | Nakamura, T., et al. 1996. Int J Hematol. 64: 39-46. PMID: 8757966
- Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). | Zomas, AP., et al. 1996. Leukemia. 10: 1966-70. PMID: 8946938
- Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. | Thompson, AA., et al. 1997. Blood. 90: 1387-94. PMID: 9269755
- Cross-linking of antigen receptor via Ig-beta (B29, CD79b) can induce both positive and negative signals in CD40-activated human B cells. | Van Kooten, C., et al. 1997. Clin Exp Immunol. 110: 509-15. PMID: 9409658
- Physical linkage of the human growth hormone gene cluster and the CD79b (Ig beta/B29) gene. | Bennani-Baïti, IM., et al. 1998. Genomics. 48: 258-64. PMID: 9521881
- Physical linkage of the B29/Ig-beta (CD79B) gene to the skeletal muscle, sodium-channel, and growth hormone genes in rat and human. | Nakazato, S., et al. 1998. Genomics. 48: 363-8. PMID: 9545642
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD79B Antibody (H-3) | sc-373843 | 200 µg/ml | $322.00 | |||
CD79B Antibody (H-3): m-IgG Fc BP-HRP Bundle | sc-540405 | 200 µg Ab; 10 µg BP | $361.00 |